Aligos Therapeutics, Inc. (5WK.F)

0,7540 +0,0480 (+6,80%) Börsenschluss: 08:02AM CEST

Aligos Therapeutics, Inc.

One Corporate Drive
2nd Floor
South San Francisco, CA 94080
United States
800 466 6059
https://www.aligos.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 66

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Lawrence M. Blatt MBA, Ph.D.	CEO, President & Chairman of the Board	963,64k	N/A	1962
Dr. Julian A. Symons DPHIL	Executive VP & Chief Scientific Officer	686,28k	N/A	1962
Dr. Sushmita M. Chanda DABT, Ph.D.	Executive Vice President & Chief Development Officer	N/A	N/A	1967
Dr. David B. Smith Ph.D.	Executive VP & Head of Chemical Operations	N/A	N/A	N/A
Dr. Tse-I Lin Ph.D.	VP of Early Compound Development & Belgian Site Head	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Corporate Governance

Aligos Therapeutics, Inc.s ISS Governance QualityScore, Stand 1. Mai 2024, lautet 9. Die grundlegenden Scores sind Audit: 9, Vorstand: 9, Shareholderrechte: 8, Kompensation: 9.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.